HCA
ADPT icon

Harbor Capital Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Harbor Capital Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.13M Buy
+145,722
New +$2.23M 0.21% 116
2026
Q1 		– Sell
-28,983
Closed -$471K – 1218
2025
Q4 		$471K Buy
+28,983
New +$473K 0.04% 499

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harbor Capital Advisors's ADPT Position: Q2 2026 in Review

Harbor Capital Advisors opened a new position in Adaptive Biotechnologies (ADPT) in Q2 2026: 145,722 shares worth $3.13M. The stake represents 0.21% of the portfolio and ranks #116 among its holdings. This is a return to the name: Harbor Capital Advisors previously reported a position in ADPT as recently as Q4 2025.

Harbor Capital Advisors first reported a position in ADPT in Q4 2025 and has held it in 2 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Harbor Capital Advisors held 145,722 shares of Adaptive Biotechnologies worth $3.13M as of Q2 2026.
  • Adaptive Biotechnologies was a new Harbor Capital Advisors position in Q2 2026.
  • Adaptive Biotechnologies made up 0.21% of Harbor Capital Advisors's portfolio in Q2 2026, its #116 holding.
  • Harbor Capital Advisors first reported a position in Adaptive Biotechnologies in Q4 2025 and has held it in 2 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.